{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:15:00Z","timestamp":1792844100469,"version":"4.5.0"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.0423","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T11:31:14Z","timestamp":1583753474000},"page":"e200423","source":"Crossref","is-referenced-by-count":284,"title":["Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs"],"prefix":"10.1001","volume":"3","author":[{"given":"Alyson","family":"Haslam","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland"},{"name":"Now with Center for Health Sciences, Oklahoma State University, Tulsa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gill","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland"},{"name":"Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland"},{"name":"Division of General Medicine, Department of Medicine, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"issue":"5","key":"zld200006r2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs.","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zld200006r3","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41571-019-0260-y","article-title":"A reality check of the accelerated approval of immune-checkpoint inhibitors.","volume":"16","author":"Gill","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"zld200006r1","unstructured":"American Cancer Society. Immune checkpoint inhibitors to treat cancer. https:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/treatment-types\/immunotherapy\/immune-checkpoint-inhibitors.html. Published 2018. Accessed January 10, 2010."},{"key":"zld200006r4","unstructured":"US Food and Drug Administration. FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-limits-use-tecentriq-and-keytruda-some-urothelial-cancer-patients. Published July 5, 2018. Accessed August 9, 2019."},{"key":"zld200006r5","unstructured":"University of Geneva. Public domain antibiotic found highly effective against triple-negative breast cancer. https:\/\/medicalxpress.com\/news\/2019-03-domain-antibiotic-highly-effective-triple-negative.html. Published March 29, 2019. Accessed August 9, 2019."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2762389\/haslam_2020_ld_200006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T11:31:17Z","timestamp":1583753477000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2762389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.0423","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]}}}